A
Alejandra Gurtman
Researcher at Pfizer
Publications - 84
Citations - 18256
Alejandra Gurtman is an academic researcher from Pfizer. The author has contributed to research in topics: Pneumococcal conjugate vaccine & Medicine. The author has an hindex of 31, co-authored 69 publications receiving 9077 citations. Previous affiliations of Alejandra Gurtman include State University of New York Upstate Medical University & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Edward E. Walsh,Robert W. Frenck,Ann R. Falsey,Ann R. Falsey,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,Kathleen M. Neuzil,Mark J. Mulligan,Ruth Bailey,Kena A. Swanson,Ping Li,Kenneth Koury,Warren Kalina,David A. Cooper,Camila R. Fontes-Garfias,Pei Yong Shi,Özlem Türeci,Tompkins Kristin Rachael,Kirsten E. Lyke,Vanessa Raabe,Philip R. Dormitzer,Kathrin U. Jansen,Ugur Sahin,William C. Gruber +25 more
TL;DR: The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.
Journal ArticleDOI
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
Mark J. Mulligan,Kirsten E. Lyke,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,Kathleen M. Neuzil,Vanessa Raabe,Ruth Bailey,Kena A. Swanson,Ping Li,Kenneth Koury,Warren Kalina,David A. Cooper,Camila R. Fontes-Garfias,Pei Yong Shi,Özlem Türeci,Tompkins Kristin Rachael,Edward E. Walsh,Edward E. Walsh,Robert W. Frenck,Ann R. Falsey,Ann R. Falsey,Philip R. Dormitzer,William C. Gruber,Ugur Sahin,Kathrin U. Jansen +26 more
TL;DR: In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose.
Journal ArticleDOI
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
Robert W. Frenck,Nicola P. Klein,Nicholas Kitchin,Alejandra Gurtman,Judith Absalon,Stephen Lockhart,John L. Perez,Emmanuel B. Walter,Shelly Senders,Ruth Bailey,Kena A. Swanson,Hua Ma,Xia Xu,Kenneth Koury,Warren Kalina,David K. C. Cooper,Timothy Jennings,Donald M Brandon,Stephen J. Thomas,Özlem Türeci,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +25 more
TL;DR: The vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of.
Journal ArticleDOI
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Emmanuel B. Walter,Kawsar R. Talaat,Charu Sabharwal,Alejandra Gurtman,Stephen Lockhart,Grant Paulsen,Elizabeth D. Barnett,Flor M. Munoz,Yvonne Maldonado,Barbara A. Pahud,Joseph B. Domachowske,Eric A. F. Simões,Uzma N. Sarwar,Nicholas Kitchin,Luke Cunliffe,Pablo Rojo,Ernest Kuchar,Mika Rämet,Iona Munjal,John L. Perez,Robert W. Frenck,Eleni Lagkadinou,Kena A. Swanson,Hua Ma,Xia Xu,Kenneth Koury,Susan Mather,Todd Belanger,David K. C. Cooper,Özlem Türeci,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +33 more
TL;DR: A phase 1, dose-finding study and an ongoing phase 2-3 randomized trial are being conducted to investigate the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in children 6 months to 11 years of age.